跳至主要内容
临床试验/NL-OMON28938
NL-OMON28938尚未招募不适用

se of individual PK-guided pazopanib dosing: A feasibility study in patients with advanced solid tumors.

Antoni van Leeuwenhoek, Amsterdam0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.
  • Note: Procedures conducted as part of the subject’s routine clinical management (e.g., blood count, imaging study such as bone scan) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol;

排除标准

  • 1. Central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria:
  • A. Are asymptomatic;

研究者

发起方
Antoni van Leeuwenhoek, Amsterdam

相似试验

PK-guided pazopanib dosing. | 临床试验